313952-63-5

DSHN is a novel activator of small heterodimer partner (SHP, NR0B2). DSHN transcriptionally activates SHP mRNA, but also stabilizes the SHP protein by preventing its ubiquitination and degradation.

DSHN is a potent small heterodimer partner (SHP) activator. DSHN inhibits Ccl2 expression and secretion by inhibiting p65 activation of Ccl2 promoter activity. DSHN can be used in research of cancer[1].

ChEBI: 5-(diethylsulfamoyl)-3-hydroxy-2-naphthalenecarboxylic acid is a member of naphthalenes and a sulfonic acid derivative.

DSHN transcriptionally activated Shp mRNA, but also stabilized the SHP protein by preventing its ubiquitination and degradation. Second, this study identified Ccl2 as a new SHP target gene by RNA-seq. This study showed that activation of SHP by DSHN repressed Ccl2 expression and secretion by inhibiting p65 activation of CCL2 promoter activity, as demonstrated in vivo in Shp-/- mice and in vitro in HCC cells with SHP overexpression and knockdown._x000D_ _x000D_ Reference: Mol Cancer Ther. 2016 Oct;15(10):2294-2301. https://pubmed.ncbi.nlm.nih.gov/27486225/

DSHN is a novel activator of small heterodimer partner (SHP, NR0B2).

[1] Yang Z, et, al. A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2. Mol Cancer Ther. 2016 Oct;15(10):2294-2301. DOI:10.1158/1535-7163.MCT-16-0153